Botox consent form

A Botox consent form is a document a patient reviews and signs before receiving Botox or another botulinum toxin injection.

It records relevant medical information, explains the proposed treatment, expected results, risks and alternatives, and documents the patient's informed consent to proceed.

A Botox consent form may include patient details, medical history, medications, allergies, previous botulinum toxin treatments, treatment areas, expected benefits, alternatives, possible risks and side effects, aftercare instructions, photography consent, and a signature.

The American Society of Plastic Surgeons recommends that patients be informed about the temporary nature of treatment, risks, benefits, alternatives, and any proposed off-label use.

Potential side effects can include bruising, injection-site pain, redness, headache, swelling, eyelid or brow drooping, and temporary facial weakness or asymmetry.

Botulinum toxin products also carry a boxed warning about the potential spread of toxin effects beyond the injection site, which in rare cases can result in problems with swallowing, speaking, or breathing.

Yes. A Botox consultation should include questions about current medications, vitamins, herbal supplements, and relevant medical treatments.

Certain medicines can interact with botulinum toxin or influence treatment decisions, so the practitioner should review relevant medication information before treatment.

Yes. The form can ask whether the patient has previously received Botox or another botulinum toxin product, when the treatment occurred, where it was injected, and whether any adverse reaction occurred.

This information can help the practitioner assess the patient's treatment history and plan the proposed procedure.

Botox is a brand of botulinum toxin type A. Other botulinum toxin products include Dysport, Xeomin, Jeuveau, and Daxxify.

Because these are different products, their units and dosing should not automatically be treated as interchangeable. The FDA prescribing information specifically states that BOTOX Cosmetic potency units cannot be directly compared or converted to units of other botulinum toxin products.

Practices may obtain comprehensive consent before an initial treatment and review or renew consent before subsequent treatments.

A new or updated form may be appropriate when treatment areas change, a different product is used, the patient's health or medication information changes, an off-label treatment is proposed, or the practice updates its consent terms.

An electronically signed Botox consent form may help document informed consent, but a signature alone does not replace an appropriate consultation and informed-consent discussion.

Medical consent, electronic signature, prescribing, and administration requirements vary by jurisdiction, so practices should customise the form and process for the laws and professional standards that apply to them.